Argentina Confirms Sputnik Light's Efficiency
The Moscow-based Russian Direct Investment Fund (RDIF) announced data from the Ministry of Health of the province of Buenos Aires, Argentina, on June 2, 2021, which confirmed the efficiency of the Sputnik Light vaccine at the level of 78.6-83.7% when vaccinating the elderly.
According to the analysis of data, more than 186 thousand people aged 60 to 79 years, more than 40 thousand of whom received an injection of the single-dose "Sputnik Light" vaccine during the mass vaccination of the population.
The data showed SARS-CoV-2 virus incidence from 21 to 40 days after receiving one vaccine injection was only 0.446%. The incidence among the adult unvaccinated population for the same period was 2.74%.
The data adjusted for age, gender, and several other parameters of vaccinated and unvaccinated people showed comparable efficacy of the Sputnik Light vaccine at the level of 78.6%.
Kirill Dmitriev, CEO of the RDIF, said in a press statement, “The publication of independent data in the province of Buenos Aires confirms the high effectiveness of the Russian vaccine for senior citizens who are at high risk."
"As follows from the report of the Ministry of Health of the province, vaccination with Sputnik Light, which is the first component of the Sputnik V vaccine, can significantly reduce the number of cases and the number of hospitalizations. We plan to continue close contact with colleagues in Argentina to study further the data on the use of the Russian vaccine."
Sputnik Light is the first component (recombinant human adenovirus 26 serotype (rAd26) of the two-dose Sputnik V vaccine. The Sputnik Light vaccine is based on a proven and well-studied platform of human adenoviral vectors, which cause the common cold.